Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Overview
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Companies Involved in Therapeutics Development
Bioasis Technologies Inc
Deli Therapeutics Inc
Esteve Pharmaceuticals SA
GC Pharma
Immusoft Corp
JCR Pharmaceuticals Co Ltd
RegenxBio Inc
ReqMed Co Ltd
Sangamo Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Drug Profiles
DNL-310 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DUOC-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EGT-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Mucopolysaccharidosis II - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Idurote 2 Sulfatase for Mucopolysaccharidosis II - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
idursulfase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
idursulfase beta - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JR-141 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pentosan polysulfate sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RGX-121 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SB-913 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
xB-3008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Dormant Projects
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Discontinued Products
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Product Development Milestones
Featured News & Press Releases
May 27, 2020: Deli Therapeutics announces publication of two new papers describing its blood-brain barrier delivery technology in science translatiol medicine
Apr 28, 2020: REGENXBIO announces presentations on RGX-121 at the American Society of Gene and Cell Therapy’s 23rd Annual Meeting
Apr 01, 2020: Clinigen and GC Pharma submit new drug application for Hunterase (Idursulfase-beta) ICV in Japan
Jan 29, 2020: REGENXBIO announces presentations at the 16th Annual WORLDSymposium 2020
Dec 18, 2019: REGENXBIO announces interim data from phase I/II trial of RGX-121 for the treatment of Mucopolysaccharidosis Type II (MPS II)
Sep 09, 2019: CANbridge Pharmaceuticals’ Hunterase Granted Priority Review by the Chinese tiol Medical Products Administration
Jul 29, 2019: CANbridge Pharmaceuticals submits New Drug Application for Hunterase for the treatment of Hunter Syndrome in Chi
Jun 11, 2019: Deli Therapeutics receives orphan drug and rare pediatric disease desigtion for DNL310, and expands its portfolio of brain penetrant enzyme replacement programs
Feb 28, 2019: JCR completes patient enrollment in phase 2 clinical trial of JR-141 for Hunter Syndrome in Brazil
Feb 28, 2019: JCR receives EMA Orphan Desigtion for JR-141 in Hunter Syndrome
Dec 28, 2018: JCR completed enrollment in phase 3 clinical trial of JR-141 in Japan for Hunter syndrome
Dec 21, 2018: Notice on the publication of the phase 1/2 clinical trial results for hunter syndrome in molecular therapy
Oct 19, 2018: JCR Pharmaceuticals: Notice of Orphan Drug Desigtion by the US Food Drug Administration for JR-141 for Hunter Syndrome
Aug 09, 2018: JCR initiates phase 3 clinical trial of JR-141 for Hunter Syndrome
Jun 29, 2018: JCR Initiates Phase 2 Clinical Trial of JR-141 for Hunter Syndrome in Brazil
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020


List of Tables


Number of Products under Development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Bioasis Technologies Inc, H1 2020
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Denali Therapeutics Inc, H1 2020
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Esteve Pharmaceuticals SA, H1 2020
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by GC Pharma, H1 2020
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Immusoft Corp, H1 2020
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by JCR Pharmaceuticals Co Ltd, H1 2020
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by RegenxBio Inc, H1 2020
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by ReqMed Co Ltd, H1 2020
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Sangamo Therapeutics Inc, H1 2020
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Dormant Projects, H1 2020
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Discontinued Products, H1 2020